| An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus D Lamarre, PC Anderson, M Bailey, P Beaulieu, G Bolger, P Bonneau, ... Nature 426 (6963), 186-189, 2003 | 1158 | 2003 |
| Hepatitis C inhibitor tri-peptides M Llinas-Brunet, MD Bailey, D Cameron, E Ghiro, N Goudreau, ... US Patent 6,323,180, 2001 | 302* | 2001 |
| Macrocyclic peptides active against the hepatitis C virus YS Tsantrizos, DR Cameron, AM Faucher, E Ghiro, N Goudreau, ... US Patent 6,608,027, 2003 | 298 | 2003 |
| Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection YS Tsantrizos, G Bolger, P Bonneau, DR Cameron, N Goudreau, G Kukolj, ... Angewandte Chemie 115 (12), 1394-1398, 2003 | 266 | 2003 |
| Structure− activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061 M Llinas-Brunet, MD Bailey, G Bolger, C Brochu, AM Faucher, JM Ferland, ... Journal of Medicinal Chemistry 47 (7), 1605-1608, 2004 | 238 | 2004 |
| Discovery of BI 224436, a noncatalytic site integrase inhibitor (NCINI) of HIV-1 LD Fader, E Malenfant, M Parisien, R Carson, F Bilodeau, S Landry, ... ACS medicinal chemistry letters 5 (4), 422-427, 2014 | 174 | 2014 |
| Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans AM Faucher, MD Bailey, PL Beaulieu, C Brochu, JS Duceppe, JM Ferland, ... Organic Letters 6 (17), 2901-2904, 2004 | 146 | 2004 |
| Viral polymerase inhibitors PL Beaulieu, S Goulet, G Kukolj, M Poirier, YS Tsantrizos, E Jolicoeur, ... US Patent 7,141,574, 2006 | 138* | 2006 |
| Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. PL Beaulieu, YS Tsantrizos Current opinion in investigational drugs (London, England: 2000) 5 (8), 838-850, 2004 | 126 | 2004 |
| Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease MA Poupart, DR Cameron, C Chabot, E Ghiro, N Goudreau, S Goulet, ... The Journal of Organic Chemistry 66 (14), 4743-4751, 2001 | 123 | 2001 |
| Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus YS Tsantrizos Accounts of chemical research 41 (10), 1252-1263, 2008 | 119 | 2008 |
| Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor C Fenwick, M Amad, MD Bailey, R Bethell, M Bös, P Bonneau, ... Antimicrobial agents and chemotherapy 58 (6), 3233-3244, 2014 | 117 | 2014 |
| Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based β-strand mimics N Goudreau, C Brochu, DR Cameron, JS Duceppe, AM Faucher, ... The Journal of Organic Chemistry 69 (19), 6185-6201, 2004 | 107 | 2004 |
| Olefin ring-closing metathesis as a powerful tool in drug discovery and development–potent macrocyclic inhibitors of the hepatitis C virus NS3 protease YS Tsantrizos, JM Ferland, A McClory, M Poirier, V Farina, NK Yee, ... Journal of Organometallic Chemistry 691 (24-25), 5163-5171, 2006 | 96 | 2006 |
| Aristolochene synthase. Elucidation of the cryptic germacrene A synthase activity using the anomalous substrate dihydrofarnesyl diphosphate DE Cane, YS Tsantrizos Journal of the American Chemical Society 118 (42), 10037-10040, 1996 | 77 | 1996 |
| Inhibitors of human immunodeficiency virus replication C Yoakim, M Bailey, F Bilodeau, R Carson, L Fader, S Kawai, S Morin, ... US Patent 8,338,441, 2012 | 70 | 2012 |
| Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers DD Waller, J Park, YS Tsantrizos Critical reviews in biochemistry and molecular biology 54 (1), 41-60, 2019 | 69 | 2019 |
| Concise and practical asymmetric synthesis of a challenging atropisomeric HIV integrase inhibitor KR Fandrick, W Li, Y Zhang, W Tang, J Gao, S Rodriguez, ND Patel, ... Angewandte Chemie International Edition 54 (24), 7144-7148, 2015 | 67 | 2015 |
| Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C … PL Beaulieu, M Bös, MG Cordingley, C Chabot, G Fazal, M Garneau, ... Journal of Medicinal Chemistry 55 (17), 7650-7666, 2012 | 67 | 2012 |
| Human isoprenoid synthase enzymes as therapeutic targets J Park, AN Matralis, AM Berghuis, YS Tsantrizos Frontiers in chemistry 2, 50, 2014 | 66 | 2014 |
